PD-1 and PD-1 ligands: from discovery to clinical application
The DOI matches its Crossref record; 133 of the 138 references it cites were found in a registry or an index.
Abstract
Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 interacts with an SHP2 tyrosine phosphatase domain, leading to dephosphorylation of signaling molecules downstream of the TCR and inhibiting TCR-mediated activation of IL2 production and T-cell proliferation (13).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Nguyen, L. T., Radhakrishnan, S., Ćirić, B., Tamada, K., Shin, T., Pardoll, D. M., Chen, L., Rodriguez, M., & Pease, L. R. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021466 · Cited by 105 · cited 1×
“However, one group reported that cross-linking of PD-L2 induces stimulatory signal in dendritic cells (DCs), resulting in the augmented antigen presentation ( 26 , 27).”
BackgroundRetractedRadhakrishnan, S., Nguyen, L. T., Ćirić, B., Ure, D., Zhou, B., Tamada, K., Dong, H., Tseng, S.-Y., Shin, T., Pardoll, D. M., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.4.1830 · Cited by 73
RetractedFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Self-citation
Cited by
Items 601–700 of 1,001
Inaba, H., Ariyasu, H., Takeshima, K., Iwakura, H., & Akamizu, T. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0234 · Cited by 25
p110δ PI3K as a therapeutic target of solid tumours
Xenou, L., & Papakonstanti, E. A. (2020) · Clinical Science · doi:10.1042/cs20190772 · Cited by 26
Choi, M. G., Kim, Y. J., Lee, J. C., Rho, J. K., & Choi, C. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13677 · Cited by 28
Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
Ma, K., Qiao, Y., Wang, H., & Wang, S. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6486 · Cited by 21
“PD-L1 is expressed in antigen-presenting cells such as dendritic cells, and in organs including the spleen, lung, heart, and liver (20).”
BackgroundLiu, Y., Li, R., Wang, X., Xue, Z., Yang, X., & Tang, B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.824938 · Cited by 24
Rudick, C. P., Cornell, D. L., & Agrawal, D. K. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1357469 · Cited by 23
“This wide dispersal allows PD-1 to have a regulatory effect on many immune response pathways from cancer to transplant rejection, and sepsis [59].”
Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports
Thomsen, K. G., Diernæs, J. E. F., Øllegaard, T. H., Spaun, E., & Vestergaard, C. (2018) · Case Reports in Dermatology · doi:10.1159/000489661 · Cited by 22
Takei, J., Ohishi, T., Kaneko, M. K., Harada, H., Kawada, M., & Kato, Y. (2020) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2020.100801 · Cited by 22
Jiang, M., Liu, M., Liu, G., Ma, J., Zhang, L., & Wang, S. (2023) · mAbs · doi:10.1080/19420862.2023.2236740 · Cited by 25
“PD-1 has an extracellular domain comprised by nine β-strands (A, A’, B, C, C’, D, E, F, G), folding into a β-sandwich Ig topology.(4,36,126) It also has eight loops connecting the β strands, and a flexible loop at the N-terminus (Figure 3).”
BackgroundS-Nitrosylation at the intersection of metabolism and autophagy: Implications for cancer
Guil‐Luna, S., Sánchez-Montero, M. T., & Rodríguez‐Ariza, A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189012 · Cited by 25
Monoclonal Antibodies and Other Targeted Therapies for Pancreatic Cancer
Cinar, P., & Tempero, M. A. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e3182758985 · Cited by 23
“Gastrin is a peptide hormone that is secreted by G cells of the gastric antrum and has been implicated in proliferation of pancreatic cancer cells.(159) As 95% of pancreatic cancers express cholecystokinin and gastrin receptor, 91% express progastrin, 55% express glycine-extended gastrin, and 23% express amidated gast…”
BackgroundLi, K., Cheng, X., Tilevik, A., Davis, S. J., & Zhu, C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.763888 · Cited by 22
“PD-1 deficiency results in spontaneous development of autoimmunity in mouse models (1, 2), and polymorphism of its gene PDCD1 in humans is associated with various autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, type I diabetes, etc., among different populations (3).”
BackgroundRecent advances in cancer immunology and immunology-based anticancer therapies
Kumar, S., Saini, R. V., & Mahindroo, N. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.126 · Cited by 24
Liver toxicity in the era of immune checkpoint inhibitors: A practical approach
Belli, C., Zuin, M. G., Mazzarella, L., Trapani, D., D’Amico, P., Guerini‐Rocco, E., Duso, B. A., & Curigliano, G. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.09.019 · Cited by 22
Cancer Stem Cell Niche and Immune-Active Tumor Microenvironment in Testicular Germ Cell Tumors
Kaľavská, K., Kučerová, L., Schmidtova, S., Chovanec, M., & Mego, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-36214-0_9 · Cited by 23
Ding, L., Dong, H., Zhou, T. R., Wang, Y. H., Yan, T., Li, J. C., Wang, Z. Y., Liang, C., & Liang, C. (2021) · Cancer Medicine · doi:10.1002/cam4.4190 · Cited by 25
Kubo, S., Yamada, T., Osawa, Y., Ito, Y., Narita, N., & Fujieda, S. (2012) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2012.04585.x · Cited by 22
Toward Localized In Vivo Biomarker Concentration Measurements
Zhang, X., Reeves, D. B., Shi, Y., Gimi, B., Nemani, K. V., Perreard, I. M., Toraya‐Brown, S., Fiering, S., & Weaver, J. B. (2015) · IEEE Transactions on Magnetics · doi:10.1109/tmag.2014.2324993 · Cited by 22
“Or the inflammation markers distinguishing successful from failed cancer immune checkpoint therapy [6]–[8] are also produced by a common cold or a bacterial infection around a simple cut.”
BackgroundZhang, J., Zhao, T., Xu, C., Huang, J., & Yu, H. T. (2016) · PubMed · doi:10.1097/md.0000000000004423 · Cited by 21
Yamada, H., Sasaki, T., Matsumoto, K., Suzuki, K., Takeshita, M., Tanemura, S., Seki, N., Tsujimoto, H., & Takeuchi, T. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa417 · Cited by 22
Pan, Q., Cheng, Y., & Cheng, D. (2021) · Journal of Immunology Research · doi:10.1155/2021/9960905 · Cited by 27
“expressed in various tumors, including liver cancer; tumor cells achieve immune escape by abnormally expressing PDL1 or PD-L2 [4].”
BackgroundInfluentialSumitomo, R., Huang, C., Fujita, M., Cho, H., & Date, H. (2022) · Oncology Reports · doi:10.3892/or.2022.8284 · Cited by 25
Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma
Tang, X. X., Shimada, H., & Ikegaki, N. (2022) · Genes and Immunity · doi:10.1038/s41435-022-00172-w · Cited by 24
“PD-L1 is a ligand of the inhibitory receptor PD-1, and the engagement of PD-L1 on PD-1 negatively modulates the function of PD-1+ cells [16].”
BackgroundVidal-Castiñeira, J. R., López‐Vázquez, A., Alonso‐Arias, R., Moro‐García, M. A., Martínez‐Camblor, P., Melón, S., Prìeto, J., López‐Rodríguez, R., Sanz-Cameno, P., Rodrigo, L., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.011 · Cited by 21
“PD-L1 is expressed in a wide variety of haematopoietic and non-haematopoietic cell types while PD-L2 is induced on dendritic cells (DC) and macrophages [19,20].”
BackgroundMoravej, A., Geramizadeh, B., Azarpira, N., Zarnani, A., Yaghobi, R., Kalani, M., Khosravi, M., Kouhpayeh, S. A., & Karimi, M. H. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.01.005 · Cited by 21
Cellular and Molecular Mechanisms of Autoimmunity and Lupus Nephritis
Devarapu, S. K., Lorenz, G., Kulkarni, O. P., Anders, H., & Mulay, S. R. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2016.12.001 · Cited by 21
Nistor, G. I., & Dillman, R. O. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02328-6 · Cited by 26
Clinical burden of immune checkpoint inhibitor-induced pneumonitis
Sakamoto, K., Fukihara, J., Morise, M., & Hashimoto, N. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.05.008 · Cited by 21
Small Extracellular Vesicles and Metastasis—Blame the Messenger
Seibold, T., Waldenmaier, M., Seufferlein, T. T. W., & Eiseler, T. (2021) · Cancers · doi:10.3390/cancers13174380 · Cited by 22
“Another mechanism of immune evasion involves binding of programmed death‐ligand 1 (PD‐L1) expressed on tumor cells and other cells in the TME to its receptor programmed cell death protein 1 (PD‐1) on activated T‐cells, thus triggering T‐cell exhaustion by suppressing activation and expansion [174,175].”
BackgroundAhmadvand, N., Carraro, G., Jones, M. R., Shalashova, I., Noori, A., Wilhelm, J., Baal, N., Khosravi, F., Chen, C., Zhang, J., et al. (2022) · Cells · doi:10.3390/cells11101593 · Cited by 22
Bojko, M., Wegrzyn, K. E., Sikorska, E., Kocikowski, M., Parys, M., Battin, C., Steinberger, P., Kogut, M. M., Winnicki, M., Sieradzan, A. K., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106047 · Cited by 23
Chun, J.-K., Kang, D. W., Yoo, B. W., Shin, J., & Kim, D. S. (2009) · European Journal of Pediatrics · doi:10.1007/s00431-009-1002-4 · Cited by 21
“It was first isolated in 1992 by Ishida and Honjo [5] and after PD-1 knockout mice was developed (1999) this gene has been studied in various autoimmune diseases, infectious diseases, transplantations, and tumor immunities extensively [13].”
BackgroundCataldi, M. P., & McCarty, D. M. (2012) · Gene Therapy · doi:10.1038/gt.2012.86 · Cited by 21
Dillman, R. O., Nistor, G. I., McLelland, B. T., Hsieh, C., Poole, A. J., Cornforth, A. N., & Keirstead, H. S. (2019) · Oncotarget · doi:10.18632/oncotarget.27164 · Cited by 20
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence
Eshaq, A. M., Flanagan, T. W., Abbad, A. A. B., Makarem, Z. A. A., Bokir, M. S., Alasheq, A. K., Asheikh, S. A. A., Almashhor, A. M., Binyamani, F., Al-Amoudi, W. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010088 · Cited by 23
Yao, Z. Q., Ni, L., Zhang, Y., Cheng, J., Zhang, C. L., Dong, Z. P., Frazier, A. D., Wu, X. Y., Thayer, P., Borthwick, T., et al. (2011) · Immunological Investigations · doi:10.3109/08820139.2010.534218 · Cited by 20
“Evidence is emerging for the involvement of PD-1 and SOCS-1 in immune tolerance, autoimmunity, and antiviral or antitumor immune evasion (Alexander, 2002; Khoury and Sayegh, 2004; Nishimra and Honjo, 2001; Okazaki and Honjo, 2007).”
BackgroundPD-L1 expression is associated with advanced non-small cell lung cancer
Chen, Z., Mei, J., Liu, L., Wang, G., Li, Z., Hou, J., Zhang, Q., You, Z., & Zhang, L. (2016) · Oncology Letters · doi:10.3892/ol.2016.4741 · Cited by 20
“The binding of PD-1 by PD-L1 and PD-L2 is now known to inhibit T cell receptor-mediated lymphocyte proliferation and cytokine secretion, thus suppressing immune responses (24).”
Hirotsu, Y., Mochizuki, H., Amemiya, K., Ohyama, H., Yoshimura, D., Amano, H., Miura, Y., Ashizawa, H., Nakagomi, K., Takaoka, S., et al. (2019) · Medical Oncology · doi:10.1007/s12032-019-1246-4 · Cited by 23
Immune checkpoint inhibitors and diabetes: Mechanisms and predictors
Youssef, N., Noureldein, M. H., Daoud, G., & Eid, A. A. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.09.003 · Cited by 20
Wu, X., Meng, Y., Liu, L., Gong, G., Zhang, H., Hou, Y., Liu, C., Wu, D., & Qin, M. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116038 · Cited by 22
Chaib, M., Sipe, L. M., Yarbro, J. R., Bohm, M. S., Counts, B. R., Tanveer, U. A., Pingili, A. K., Daria, D., Marion, T. N., Carson, J. A., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.017 · Cited by 23
Wang, B., Chen, C., Liu, X., Zhou, S. Y., Xu, T., & Wu, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111005 · Cited by 25
First-line ICIs in renal cell carcinoma
Fiorentino, V., Tralongo, P., Larocca, L. M., Pizzimenti, C., Martini, M., & Pierconti, F. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2225386 · Cited by 23
“Generally speaking, PD-1 inhibition is thought to be less harmful and more effective against tumors than CTLA-4 inhibition because PD-1 predominantly regulates the effector phase of T-cell responses and has a stronger selectivity for immune suppressive signals that are directly transmitted by cancer.(23,24)”
BackgroundStructure of PD1 and its mechanism in the treatment of autoimmune diseases
Rezayi, M., & Hosseini, A. (2023) · Cell Biochemistry and Function · doi:10.1002/cbf.3827 · Cited by 20
“PD1 is a type I transmembrane glycoprotein and consists of an IgV‐type extracellular domain, a trans‐membrane region, and an intracellular tail.(9) The extracellular domain stands for”
BackgroundYoung, J. S., Heffernan, D. S., Chung, C., Kettenmann, M. L., Young, W. A., Guillen, V. S., Cioffi, W. G., & Ayala, A. (2015) · Shock · doi:10.1097/shk.0000000000000553 · Cited by 20
Medical treatment for gastro-entero-pancreatic neuroendocrine tumours
Berardi, R., Morgese, F., Torniai, M., Savini, A., Partelli, S., Rinaldi, S., Caramanti, M., Ferrini, C., Falconi, M., & Cascinu, S. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i4.389 · Cited by 23
An, Q., & Liu, Z. (2019) · BMC Cancer · doi:10.1186/s12885-018-5259-8 · Cited by 25
Xie, Q., Wang, L., & Zheng, S. (2020) · Disease Markers · doi:10.1155/2020/1817931 · Cited by 20
“The immune checkpoint molecules, programmed cell death-1 (PD-1) and its ligand programmed death-ligand-1 (PD-L1), regulate immune responses in cancer development [8].”
BackgroundChou, C., Yang, R., Chan, L.-C., Li, C.-F., Sun, L., Lee, H., Lee, P., Sher, Y., Ying, H., & Hung, M. (2020) · PubMed Central · Cited by 40
Harada, M., Naoi, H., Yasuda, K., Ito, Y., Kagoo, N., Kubota, T., Ichijo, K., Mochizuki, E., Uehara, M., Matsuura, S., et al. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01375-5 · Cited by 20
“Furthermore, only 40% homology has been reported among the two ligands [12].”
BackgroundWu, J.-F., Hsu, H.-Y., Ni, Y.-H., Chen, H.-L., Wu, T.-C., & Chang, M.-H. (2012) · American Journal of Pathology · doi:10.1016/j.ajpath.2012.03.036 · Cited by 25
Natarajan, N., Telang, S., Miller, D. M., & Chesney, J. A. (2011) · Drugs · doi:10.2165/11591380-000000000-00000 · Cited by 18
Yang, X., & Liu, J. (2021) · Bioengineered · doi:10.1080/21655979.2021.1983278 · Cited by 21
Polesel, J., Menegaldo, A., Tirelli, G., Giacomarra, V., Guerrieri, R., Baboçi, L., Casarotto, M., Lupato, V., Fanetti, G., Boscolo‐Rizzo, P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.787864 · Cited by 19
Davoodi‐Moghaddam, Z., Jafari‐Raddani, F., Noori, M., & Bashash, D. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101636 · Cited by 21
“PD-1 is a monomeric molecule with an intracellular domain containing an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM) motif, as well as an extracellular immunoglobulin-like domain [6].”
BackgroundNavigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities
Badenhorst, M., Windhorst, A. D., & Beaino, W. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1401515 · Cited by 20
“PD-L1 is overexpressed on tumor cells and the immunoregulatory interaction with PD-1 equips the tumor to successfully evade anti-tumor activity (6, 7, 11–13).”
BackgroundJanelle, V., Langlois, M.-P., Lapierre, P., Charpentier, T., Poliquin, L., & Lamarre, A. (2014) · Molecular Therapy · doi:10.1038/mt.2014.34 · Cited by 19
Established, emerging and elusive molecular targets in the treatment of lung cancer
Gallant, J., & Lovly, C. M. (2018) · The Journal of Pathology · doi:10.1002/path.5038 · Cited by 26
“PD-1, a cell surface checkpoint receptor belonging to the CD28/cytotoxic T-lymphocyte-associated protein 4 family, negatively regulates antigen receptor signalling (by recruiting protein tyrosine phosphatase SHP-2 to the cell membrane) upon interacting with either of two ligands, PD-L1 or programmed death-ligand 2 [10…”
BackgroundAdoptive cell transfer: new perspective treatment in veterinary oncology
Bujak, J. K., Pingwara, R., Nelson, M. H., & Majchrzak, K. (2018) · Acta veterinaria Scandinavica · doi:10.1186/s13028-018-0414-4 · Cited by 24
Sternschein, R. M., Moll, M. R., Ng, J., & D’Ambrosio, C. M. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201803-0525rr · Cited by 19
Al-Khami, A. A., Youssef, S., Abdiche, Y. N., Nguyen, H. T., Chou, J., Kimberlin, C. R., Chin, S. M., Kamperschroer, C., Jessen, B. A., Kern, B., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0093 · Cited by 18
“In-line with the published PD-1 expression pattern (45, 46), tissue cross-reactivity studies revealed staining in mononuclear cell types, including T and B lymphocytes, and myeloid cell subtypes.”
Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion
Chan, Y. T., Cheong, H. C., Tang, T. F., Rajasuriar, R., Cheng, K., Looi, C. Y., Wong, W. F., & Kamarulzaman, A. (2022) · Biomedicines · doi:10.3390/biomedicines10112809 · Cited by 23
“PD-1 receptor is the most extensively studied exhaustion factor that exerts a negative impact on T cells through binding to programmed death-ligand 1 (PD-L1) or PD-L2 [19].”
BackgroundEmerging drugs for the treatment of alopecia areata
Ramírez-Marín, H. A., & Tosti, A. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2149735 · Cited by 27
“regulation of T cell mediated immune responses [57,58].”
BackgroundCurrent studies and future promises of PD-1 signal inhibitors in cervical cancer therapy
Awadasseid, A., Zhou, Y., Zhang, K., Tian, K., Wu, Y., & Zhang, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114057 · Cited by 19
Kim, S.-B., Hwang, S., Cha, J.-Y., & Lee, H.-J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052939 · Cited by 20
“The full-length protein is ~31 kDa and comprises 290 amino acids, with the extracellular region exhibiting approximately 20% amino acid identity with B7-1, another significant immunological player [6,16].”
BackgroundDevelopment of small molecule drugs targeting immune checkpoints
Chen, L., Zhao, X., Liu, X., Ouyang, Y., Xu, C. S., & Shi, Y. K. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0034 · Cited by 32
“Once combined, the PD-1 and PD-L1 signal recruits SHP2 to block the activation of various phosphatases (e.g., AKT and ERK) 68 , leading to impaired immune signals and the T cell immune response 69 .”
BackgroundSchuchmann, M., Meyer, R. G., Distler, E., von Stebut, E., Kuball, J. H. E., Schnürer, E., Wölfel, T., Theobald, M., Konur, A., Gregor, S., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02401.x · Cited by 19
“Proinflammatory cytokines such as IFN-c and TNF-a are known to upregulate PD-L1 on various hematopoietic and nonhematopoietic cells (16,40,46) including keratinocytes (47– 49).”
BackgroundOkuma, Y., Hishima, T., Kashima, J., & Homma, S. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2103-y · Cited by 18
“On the other hand, the immune checkpoint mechanism through PD-1/PD-L1 pathway plays a pivotal role in the suppression of antitumor immunity and evasion of tumors from immunological attack [22].”
BackgroundThe PD-1 rs36084323 A > G polymorphism decrease cancer risk in Asian: A meta-analysis
Da, L., Zhang, Y., Zhang, C., Bu, L., Zhu, Y., Ma, T., & Gu, K. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.09.015 · Cited by 18
Raaijmakers, T. K., van den Bijgaart, R. J. E., den Brok, M. H., Wassink, M., de Graaf, A. M. A., Wagenaars, J. A. L., Nierkens, S., Ansems, M., Scheffer, G. J., & Adema, G. J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000649 · Cited by 21
Wagner, M., Tupikowski, K., Jasek, M., Tomkiewicz, A., Witkowicz, A., Ptaszkowski, K., Karpiński, P., Zdrojowy, R., Hałoń, A., & Karabon, L. (2020) · Cancers · doi:10.3390/cancers12123521 · Cited by 22
“Programmed death receptor-1 (PD-1) is a member of CD28 family, expressed on double negative αβ and γδ T cells in thymus and activated T and B cells [4,5].”
BackgroundA pan-cancer study of PD-1 and CTLA-4 as therapeutic targets
Cai, Z., Ang, X., Xu, Z., Li, S., Zhang, J., Pei, C.-S., & Zhou, F. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-561 · Cited by 20
“PD-1 is an immune receptor which belongs to the CD28/CTLA-4 series (17), a member 4”
BackgroundT-cell-intrinsic and -extrinsic regulation of PD-1 function
Sugiura, D., Shimizu, K., Maruhashi, T., Okazaki, I., & Okazaki, T. (2021) · International Immunology · doi:10.1093/intimm/dxab077 · Cited by 17
Veinalde, R., Pidelaserra-Martí, G., Moulin, C., Jeworowski, L. M., Küther, L., Buchholz, C. J., Jäger, D., Ungerechts, G., & Engeland, C. E. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.11.020 · Cited by 23
“PD-1/PD-L1 blockade with monoclonal antibodies has proved to be a successful therapeutic strategy to reinvigorate anti-tumor immunity.(4) Six different monoclonal antibodies for PD-1/PD-L1 blockade have been approved by the U.”
BackgroundPD-1 Regulates Neural Damage in Oligodendroglia-Induced Inflammation
Kroner, A., Schwab, N., Ip, C. W., Leder, C., Nave, K., Mäurer, M., Wiendl, H., & Martini, R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004405 · Cited by 18
“homeostasis and autoimmunity [10,11].”
Beattie, J., Yarmus, L. B., Wahidi, M. M., Rivera, M. P., Gilbert, C. R., Maldonado, F., Czarnecka, K., Argento, A. C., Chen, A. J., Herth, F. J. F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201712-2539pp · Cited by 19
Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation
Fayyad‐Kazan, M., Al-Tameemi, S. A., & Ouhtit, A. (2026) · Cells · doi:10.3390/cells15050393 · Cited by 17
Donnelly, L. L., Hogan, T. C., Lenahan, S. M., Nandagopal, G., Eaton, J. G., Lebeau, M. A., McCann, C., Sarausky, H. M., Hampel, K. J., Armstrong, J. D., et al. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab104 · Cited by 18
Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer
Khadela, A. D., Chavda, V. P., Postwala, H. I., Ephraim, R., Apostolopoulos, V., & Shah, Y. B. (2023) · Cancers · doi:10.3390/cancers15020543 · Cited by 18
d-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity
Dong, W., Lin, M., Zhang, R., Sun, X., Li, H., Liu, T., Xu, Y., & Lv, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216883 · Cited by 19
Recent advances in immunotherapy in cancer treatment
Patel, A. A. (2024) · Cellular and Molecular Biology · doi:10.14715/cmb/2024.70.5.13 · Cited by 19
“It was the identification of immune checkpoint molecules, such as CTLA-4 [29] and PD-1 [30], in the 1990s and early 2000s, that paved the way for the development of checkpoint in - hibitors.”
BackgroundEbrahimnezhad, S., Jazayeri, M. H., Hassanian, S. M., & Avan, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25765 · Cited by 17
“This receptor is associated with immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy, and immunological privilege (Okazaki & Honjo, 2007).”
BackgroundHayashi, H., Chiba, Y., Sakai, K., Fujita, T., Yoshioka, H., Sakai, D., Kitagawa, C., Naito, T., Takeda, K., Okamoto, I., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.012 · Cited by 17
Skin-Resident T Cells Drive Dermal Dendritic Cell Migration in Response to Tissue Self-Antigen
Ali, N., Zirak, B., Truong, H.-A., Maurano, M. M., Gratz, I. K., Abbas, A. K., & Rosenblum, M. D. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701206 · Cited by 18
Viral Infections and Autoimmune Disease: Roles of LCMV in Delineating Mechanisms of Immune Tolerance
Fousteri, G., & Jhatakia, A. (2019) · Viruses · doi:10.3390/v11100885 · Cited by 17
PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity
van Ens, D., Mousset, C. M., Hutten, T. J. A., van der Waart, A. B., Campillo-Davó, D., van der Heijden, S., Vodegel, D., Fredrix, H., Woestenenk, R., Vidal, L. P., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0966-6 · Cited by 17
Tick saliva-induced programmed death-1 and PD-ligand 1 and its related host immunosuppression
Sajiki, Y., Konnai, S., Ikenaka, Y., Gulay, K. C. M., Kobayashi, A., Parizi, L. F., João, B. C., Watari, K., Fujisawa, S., Okagawa, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-80251-y · Cited by 23
High Levels of Thyroid Hormone Impair Regulatory T Cell Function Via Reduced PD-1 Expression
Zhong, Y., Lü, T., Liu, X., Liu, B., Hu, Y., Liu, S., Wang, J., Li, G., & Mao, X. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab191 · Cited by 21
Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy
Ishii, H., Afify, S. M., Hassan, G., Salomon, D. S., & Seno, M. (2021) · Cancers · doi:10.3390/cancers13102491 · Cited by 18
“Therefore, ICIs allow activated T cells to recognize and attack tumor cells [9,10].”
BackgroundImmune checkpoints and the multiple faces of B cells in systemic lupus erythematosus
Stefanski, A., & Dörner, T. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000825 · Cited by 21
“associated with susceptibility to SLE [50].”
Recent insights into the pathogenesis of autoimmune hypophysitis
Frasca, F., Piticchio, T., Moli, R. L., Malaguarnera, R., Campennì, A., Cannavò, S., & Ruggeri, R. M. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1974297 · Cited by 17
Hassan, W. A., Baraka, E., & Fouad, N. A. (2015) · The Egyptian Rheumatologist · doi:10.1016/j.ejr.2014.12.002 · Cited by 22
“PD-L1 is broadly expressed in both hematopoietic and non hematopoietic tissues and is upregulated on activated T cells, B cells, macrophages, and DCs upon stimulation, while PD-L2 expression is restricted to activated macrophages and dendritic cells (DCs) [12].”
BackgroundPyzik, A., Grywalska, E., Matyjaszek‐Matuszek, B., Smoleń, A., Pyzik, D., & Roliński, J. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.03.006 · Cited by 17
Tajbakhsh, A., Farahani, N., Gheibihayat, S. M., Mirkhabbaz, A. M., Savardashtaki, A., Hamblin, M. R., & Mirzaei, H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107177 · Cited by 17
Cardiovascular adverse effects of immunotherapy in cancer: insights and implications
Du, H., Wang, J., & Wang, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1601808 · Cited by 22
“CTLA-4, on the other hand, mostly controls T-cell proliferation in lymphoid organs during the early stages of immunological activation (136 – 142).”
Nowicki, T. S., Anderson, J. L., & Federman, N. C. (2015) · Pediatric Research · doi:10.1038/pr.2015.246 · Cited by 18
Mishra, A., Majid, D. S. A., Kandikattu, H. K., Yadavalli, C. S., & Venkateshaiah, S. U. (2021) · Allergy · doi:10.1111/all.15180 · Cited by 18
TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes
Trivedi, P., Jhala, G., George, D. J. D., Chiu, C. Y. H., Selck, C., Ge, T., Catterall, T., Elkerbout, L., Boon, L., Joller, N., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1370907 · Cited by 19
Developing melanoma therapeutics: overview and update
Korman, J. B., & Fisher, D. E. (2013) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1210 · Cited by 18
Intralesional and systemic immunotherapy for metastatic melanoma
Luu, C., Khushalani, N. I., & Zager, J. S. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1233961 · Cited by 16
Metadata
- Authors
- Okazaki, T., & Honjo, T.
- Affiliations
- Kyoto University (JP)
- ORCID
- Okazaki, T.
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-22
- Volume
- 19
- Issue
- 7
- Pages
- 813-824
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- OpenAlex
- W2122639773
- Cited by
- 1,310
- References
- 138
- Citations by year
- 2026: 26 · 2025: 53 · 2024: 96 · 2023: 94 · 2022: 100 · 2021: 125 · 2020: 152 · 2019: 101 · 2018: 100 · 2017: 112 · 2016: 72 · 2015: 70 · 2014: 41 · 2013: 48 · 2012: 29
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Biomedical Innovation
- Japan Society for the Promotion of Science (17047024, 19689012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, PD-L1, PD-L2, immune checkpoint, SHP2, autoimmunity, antitumor immunity, transplantation immunity, allergy, immune privilege, clinical application
- MeSH terms
- Animals, Autoimmune Diseases, Humans, Immunity, Ligands, Antigens, CD, Intercellular Signaling Peptides and Proteins, Mice, B7-H1 Antigen, Programmed Cell Death 1 Ligand 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.